Sagimet Biosciences Inc. (SGMT) stock
Close on Nov 11, 2026Market cap $709.23MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $709.23M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.93
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$53.32M
- EPS, diluted
- -$1.19
- Book value per share
- $3.88
- Diluted shares
- 62M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $10.89
- Open
- $10.93
- Day's range
- $10.80 – $11.44
- Volume
- 1,790,293
- Average volume (20 days)
- 1,152,150
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 3.17
- 52-week range
- $4.50 – $11.45
- RSI (14 days)
- 63.5
- Volatility (1 year)
- 82.5%
- Relative volume
- 1.46×
- WACC
- 17.4%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SGMT | S&P 500 | Difference | SGMT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +27.8% | -2.4% | +30.2 pts | ||
| 3 months | +19.9% | -1.2% | +21.0 pts | ||
| Year to date | +92.7% | +12.3% | +80.4 pts | ||
| 1 year | +34.2% | +12.4% | +21.8 pts | ||
| 3 years | +341.4% | +78.8% | +262.6 pts | +64.0% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Sagimet Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About Sagimet Biosciences
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical firm that develops oral therapeutics targeting dysfunctional metabolic and fibrotic pathways. Its research focuses on fatty acid synthase inhibitors designed to treat conditions caused by excess palmitate production. Its primary drug candidate is denifanstat, an oral daily medication being evaluated for metabolic dysfunction-associated steatohepatitis, moderate to severe acne, and specific forms of cancer. Its secondary pipeline asset is TVB-3567, a small molecule candidate also aimed at treating acne. The company designs its therapies for patients suffering from liver disease, dermatological disorders, and solid tumors, and it works with commercial biopharmaceutical partners such as Ascletis to advance programs in designated territories.
Company profile, executives and historySagimet Biosciences stock: common questions
What is Sagimet Biosciences's stock price?
SGMT closed at $11.41 on Nov 11, 2026, up 4.78% on the day. Over the past 52 weeks it traded between $4.50 and $11.45.
What is Sagimet Biosciences's market cap?
Sagimet Biosciences was worth $709.23M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SGMT's P/E ratio?
Sagimet Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.19), so it has no meaningful P/E ratio.
Does Sagimet Biosciences pay a dividend?
No. Sagimet Biosciences has not paid a cash dividend over the last twelve months.
When does Sagimet Biosciences report earnings next?
Sagimet Biosciences is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SGMT stock performed over the past year?
Including dividends, SGMT returned +34.2% over the past year, against +12.4% for the S&P 500.
How many SGMT shares are sold short?
12M shares were sold short at the latest FINRA report, 20.02% of the float, or 10.5 days of average trading volume.
Who are Sagimet Biosciences's competitors?
Companies most similar to Sagimet Biosciences by business, industry and size include VTVT, GPCR, IVA, ALT, MDGL.
See a number that looks wrong?